/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Rein Therapeutics Inc share price today is $1.3, up 1.59%. The stock opened at $1.33 against the previous close of $1.26, with an intraday high of $1.34 and low of $1.3.

style

pb-0

Rein Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$1.3 0.0159(1.59%) RNTX at 13 Mar 2026 03:03 PM Biotechnology

Lowest Today 1.3

Highest Today 1.34

Today’s Open 1.33

Prev. Close 1.26

52 Week High 2.40

52 Week Low 1.02

Day’s Range: Low 1.3 High 1.34

52-Week Range: Low 1.02 High 2.40

Rein Therapeutics Inc Institutional Holdings

Rein Therapeutics Inc Market Status

Strong Buy: 1

Buy: 0

Hold: 0

Sell: 0

Strong Sell: 0

Rein Therapeutics Inc Fundamentals

Market Cap 33.12 M

PB Ratio 27.9501

PE Ratio 0.0

Enterprise Value 15.86 M

Total Assets 69.24 M

Volume 144853

Rein Therapeutics Inc Company Financials

About Rein Therapeutics Inc & investment objective

Company Information Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.

Organisation Biotechnology

Employees 11

Industry Biotechnology

CEO Dr. James Brian Windsor Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*